It has been shown that C-reactive protein levels may not rise in the case of bacterial infection in patients treated with tocilizumab [28], and, given the rising number of molecular-targeted immunosuppressive drugs, it is possible that other drugs may have the same effect. The gene discussed is CRP; the disease is bacterial infectious disease.